The kl-A289 injection, an innovative drug in Collum Pharmaceuticals, was approved clinically.

Guide: KL-A289 injections are intended for the treatment of advanced solid tumors. on August 4,
, Collum Pharmaceuticals announced that KL-A289 injections of the innovative tumor immunology drug COlumbotai BiopharmaceuticalCoB.e., a controlling subsidiary of the Company, and Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd., had been approved by the State Drug Administration for clinical trials.
KL-A289 injection is a new generation of tumor immunocheckpoint inhibitors jointly developed by Colleen Pharmaceuticals and Anyuan Pharmaceuticals with independent intellectual property rights, the mechanism of action is relatively clear, which can lift the inhibition of anti-tumor T cells, enhance the body's immune response to tumors, and is intended to be used in the treatment of advanced solid tumors.
preclinical studies show that KL-A289 injections show anti-tumor activity in single drugs in tumor animal models, and have the potential of combination with other immunocheckpoint inhibitors, chemotherapy drugs, etc., and have good pharmacokinetic characteristics, both good safety and tolerance.
, after inquiry, there is no global target drug approved for market.
.